We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01833039
First Posted: April 16, 2013
Last Update Posted: September 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Biotech, Inc.
April 6, 2013
April 16, 2013
September 21, 2017
May 15, 2013
September 29, 2017   (Final data collection date for primary outcome measure)
Percentage of Patients With Treatment Emergent Adverse Experiences during the study. [ Time Frame: Start of study drug to 30 Days post study drug administration ]
Percentage of Patients With Treatment Emergent Adverse Experiences during the study.
Number of Patients with Adverse Events as a Measure of Safety [ Time Frame: Start of study drug to 30 Days post study drug administration ]
The Number of Patients With Treatment Emergent Adverse Experiences of Interest During The Study. Averse Experiences of Interest are: Major Hemorrhage, Intracranial Hemorrhage, Pregnancy.
Complete list of historical versions of study NCT01833039 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Relapsed or Refractory Mantle Cell Lymphoma
Drug: Ibrutinib
Ibrutinib
Experimental: Ibrutinib
Ibrutinib
Intervention: Drug: Ibrutinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
163
September 29, 2017
September 29, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.

Exclusion Criteria:

  • Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
  • Patients previously treated with ibrutinib are not eligible.
  • Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   Puerto Rico,   United States
 
 
NCT01833039
CR101862
PCI-32765MCL4001 ( Other Identifier: Janssen )
No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Janssen Biotech, Inc.
Janssen Biotech, Inc.
Pharmacyclics LLC.
Not Provided
Janssen Biotech, Inc.
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP